Breast Cancer | Specialty

Dr. Silverstein on Oncoplasty Versus Mastectomy for Patients With Breast Cancer

July 31st 2015

Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.

Dr. Edith Mitchell on Cancer Disparities Among African American Patients

July 29th 2015

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer

July 29th 2015

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.

Progress in HER2-Positive Breast Cancer Comes With Successes and Setbacks

July 22nd 2015

Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.

Investigational Targeted Therapies for Breast Cancer

July 21st 2015

PARP Inhibitors in Triple-Negative Breast Cancer

July 21st 2015

Anti-HER2 Therapy for Metastatic Breast Cancer

July 21st 2015

PI3K Inhibition in Breast Cancer

July 21st 2015

Overcoming Endocrine Resistance in Breast Cancer

July 21st 2015

CDK4/6 Inhibition in Breast Cancer

July 21st 2015

Advancements in ER-Positive Breast Cancer

July 21st 2015

Guiding Treatment With Molecular Testing in Breast Cancer

July 21st 2015

Efforts Continue to Refine Neoadjuvant HER2+ Breast Cancer Care

July 21st 2015

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

Dr. Kass on Testing for HER2-Positive Breast Cancer

July 20th 2015

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Dr. Nanda on Immunotherapy in Metastatic TNBC

July 18th 2015

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

Dr. Chlebowski on Dietary Modifications in Patients With Breast Cancer

July 17th 2015

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

Everolimus Activity Linked With PIK3CA/PTEN Status in HER2-Positive Breast Cancer

July 16th 2015

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

Neoadjuvant T-DM1 Shows Promising pCR Rates in HER2+/HR+ Early Breast Cancer

June 23rd 2015

Chemotherapy-free neoadjuvant treatment with trastuzumab emtansine demonstrated a pathological complete response rate of 40.5% in patients with HER2+ and HR+ early breast cancer.

O'Regan Discusses Breast Cancer Index, Molecular Profiling in HER2+ Breast Cancer

June 23rd 2015

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer

June 22nd 2015

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.